These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16015536)

  • 1. Pulmonary toxicity associated with the treatment of non-small cell lung cancer and the effects of cytoprotective strategies.
    Gopal R
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S55-9. PubMed ID: 16015536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical trial.
    Wynn RB; Mehta V
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S99-104. PubMed ID: 16015543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
    Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
    Antonadou D
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
    Komaki R; Lee JS; Kaplan B; Allen P; Kelly JF; Liao Z; Stevens CW; Fossella FV; Zinner R; Papadimitrakopoulou V; Khuri F; Glisson B; Pisters K; Kurie J; Herbst R; Milas L; Ro J; Thames HD; Hong WK; Cox JD
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):46-9. PubMed ID: 11917284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-small cell lung cancer: the role of cytoprotection in treating therapy-related toxicity.
    Gopal R
    J Support Oncol; 2004; 2(6 Suppl 3):13-7. PubMed ID: 15605920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
    Antonadou D; Throuvalas N; Petridis A; Bolanos N; Sagriotis A; Synodinou M
    Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):402-8. PubMed ID: 12957251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioprotective effect of amifostine in radiation pneumonitis.
    Choi NC
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):10-7. PubMed ID: 14727236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy.
    Komaki R; Chang JY; Wu X; Allen PK; Milas L; Liao Z; Fossella FV; Travis E; Spitz MR
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S92-8. PubMed ID: 16015542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amifostine in chemoradiation therapy for non-small cell lung cancer: review of experience and design of a phase II trial assessing subcutaneous and intravenous bolus administration.
    Werner-Wasik M; Langer C; Movsas B
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S105-8. PubMed ID: 16015544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
    Mehta V
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    Komaki R; Lee JS; Milas L; Lee HK; Fossella FV; Herbst RS; Allen PK; Liao Z; Stevens CW; Lu C; Zinner RG; Papadimitrakopoulou VA; Kies MS; Blumenschein GR; Pisters KM; Glisson BS; Kurie J; Kaplan B; Garza VP; Mooring D; Tucker SL; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1369-77. PubMed ID: 15050312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
    Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
    J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
    Senzer N
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):38-41. PubMed ID: 12577242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-related esophagitis.
    Werner-Wasik M
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S60-6. PubMed ID: 16015537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does more aggressive therapy improve outcomes in the treatment of unresectable stage III non-small cell lung cancer?
    Rosenman JG; Socinski MA
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S13-7. PubMed ID: 16015531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.
    Werner-Wasik M; Langer C; Movsas B
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):47-51. PubMed ID: 15726523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
    Antonadou D; Coliarakis N; Synodinou M; Athanassiou H; Kouveli A; Verigos C; Georgakopoulos G; Panoussaki K; Karageorgis P; Throuvalas N;
    Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):915-22. PubMed ID: 11704311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
    Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
    J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the use of amifostine improve cure rates for patients with advanced non-small cell lung cancer?
    Rosenman J
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):52-8. PubMed ID: 15726524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.